Top 10 Daridorexant (Quviviq) Generic Manufacturers in Canada
The Canadian pharmaceutical market is experiencing significant growth, particularly in the generics sector. With a market size projected to reach CAD 22 billion by 2024, the demand for affordable medications is fueling the rise of generic manufacturers. Notably, the global generic drug market is expected to grow at a CAGR of 6.5%, highlighting the increasing emphasis on cost-effective treatment options. Daridorexant, marketed as Quviviq, is gaining traction for its application in treating insomnia, and several companies are vying to capitalize on this trend in Canada.
1. Teva Canada Limited
Teva Canada is one of the leading generic drug manufacturers in Canada, holding approximately 17% of the market share. The company has a robust portfolio, including a generic version of daridorexant, contributing to its annual revenue of over CAD 1.5 billion. Teva’s extensive distribution network ensures widespread accessibility of its products.
2. Apotex Inc.
With a production volume of over 300 million units annually, Apotex is a major player in the Canadian generics market. The company is known for its innovation in drug formulation and has recently launched a generic version of Quviviq, which is expected to capture a significant share of the insomnia treatment segment. Apotex’s market share is estimated at around 15%.
3. Sandoz Canada Inc.
Sandoz, a Novartis division, commands a solid position in the generic pharmaceuticals arena, with an estimated market share of 11%. The company has a diverse portfolio, including a newly introduced daridorexant generic. Sandoz’s commitment to quality and regulatory compliance ensures its products meet high standards, which enhances its competitive edge.
4. Mylan Pharmaceuticals ULC
Mylan, now part of Viatris, is recognized for its extensive range of generic medications, including a focus on neuropsychiatric drugs. Mylan’s daridorexant generic has been well-received, contributing to a market share of approximately 10%. The company’s production capacity exceeds 200 million units, showcasing its ability to meet growing demands.
5. Fresenius Kabi Canada Ltd.
Fresenius Kabi specializes in generic injectables and biosimilars, with a growing interest in oral medications like daridorexant. The company holds about 6% of the Canadian generics market, with plans to expand its portfolio further. Its commitment to high-quality standards ensures that its products maintain a strong reputation among healthcare providers.
6. Valeant Pharmaceuticals International, Inc.
Valeant, now known as Bausch Health, has diversified its offerings to include generics. The company holds around 5% of the market share and has recently launched a generic daridorexant. Bausch Health’s strategic focus on insomnia treatments positions it well within the competitive landscape.
7. HLS Therapeutics Inc.
HLS Therapeutics is known for its specialized generic products in the CNS segment. The company has a market share of approximately 4% and has initiated the production of a daridorexant generic, targeting niche markets within the insomnia treatment space.
8. Knight Therapeutics Inc.
Knight Therapeutics primarily focuses on acquiring and commercializing innovative pharmaceuticals. Although its market share is smaller at about 3%, the company has made strides in developing a generic version of daridorexant. Knight’s strategic partnerships enhance its market reach and distribution capabilities.
9. Cobalt Pharmaceuticals Inc.
Cobalt Pharmaceuticals operates in the generic space with a focus on high-quality manufacturing standards. With a market share of around 2.5%, the company has recently introduced a generic version of daridorexant in line with market trends, aiming to capture a share of the growing insomnia treatment market.
10. Pharmascience Inc.
Pharmascience is one of the top Canadian generics manufacturers, holding a market share of approximately 2%. The company has launched its own version of daridorexant, aiming to cater to the rising demand for insomnia medications in Canada. With a production capacity that allows flexibility, Pharmascience is well-positioned for future growth.
Insights
The Canadian market for daridorexant generics is poised for growth, driven by an increasing prevalence of insomnia and heightened demand for affordable treatment options. As the generics sector continues to expand, manufacturers are investing in research and development to improve drug formulations and enhance efficacy. The market is expected to grow by 5% annually over the next five years, reflecting a broader trend toward generic adoption in Canada. With more players entering the market, competition will likely lead to reduced prices and improved access for consumers, aligning with the overarching goal of making healthcare more affordable.
Related Analysis: View Previous Industry Report
